

SITUATION

- Safety events and drug waste have occurred secondary to uncertainty regarding parenteral chemotherapy/biotherapy administration outside of the Oncology Unit (5-West).

BACKGROUND

- Parenteral chemotherapy/biotherapy agents must only be administered by registered nurses with current chemotherapy/biotherapy certification. [POLICY #NMO-001]
- Registered nurses with this certification work primarily on the Oncology Unit.
- However, chemotherapy/biotherapy agents may be ordered on any unit for oncological and non-oncological indications.

ASSESSMENT

IV Chemo & Biotherapy	SQ/IM Chemo & Biotherapy
<p>• Medical Telemetry Units: Patient will be transferred to Oncology unit.</p> <p>• Critical Care Units, PCU, Cardiac Telemetry: Chemotherapy trained RN from the Oncology unit will go to the unit for administration if patient is not stable enough for transfer to the Oncology unit.</p>	<p>• Chemotherapy/biotherapy trained RN from 5W will go to the unit for administration.</p>

Chemotherapy agents*	
IV	SQ/IM
<ul style="list-style-type: none"> • Azacitidine (VIDAZA) • Bendamustine (BENDEKA) • Bleomycin (BLENOXANE) • Carboplatin (PARAPLATIN) • Cisplatin (PLATINOL) • Cyclophosphamide (CYTOXAN) • Cytarabine (CYTOSAR) • Dactinomycin (COSMEGEN) • Daunorubicin (CERBUIDINE) • Dectiabine (DACOGEN) • Doxorubicin (ADRIAMYCIN, DOXIL) • Epirubicin (ELLENCE) • Etoposide (TOPOSAR) • Fluorouracil (ADRUCIL) • Gemcitabine (GEMZAR) • Idarubicin (IDAMYCIN) • Ifosfamide (IFEX) • Irinotecan (CAMPTOSAR) • Methotrexate • Oxaliplatin (ELOXATIN) • Paclitaxel (TAXOL) • Vinblastine (VELBAN) • Vincristine (ONCOVIN) • Vinorelbine (NAVELBINE) 	<ul style="list-style-type: none"> • Azacitidine (VIDAZA) • Bleomycin (BLENOXANE) • Bortezomib (VELCADE) • Cytarabine (CYTOSAR) • Methotrexate
Biotherapy agents	
IV	SQ/IM
<ul style="list-style-type: none"> • Bevacizumab (AVASTIN) • Infliximab (REMICADE, INFLECTRA) • Ofatumumab (ARZERRA) • Rituximab (RITUXAN, TRUXIMA) • Trastuzumab (HERCEPTIN) • Tocilizumab (ACTEMRA) 	<ul style="list-style-type: none"> • Adalimumab (HUMIRA) • Tocilizumab (ACTEMRA)

*This list is not an all-inclusive list of every chemotherapy/biotherapy agent.

References:

OLOLRMC Chemotherapy (Cytotoxic agents), Handling, Administration and Disposal (Policy #NMO-001)

Updated: June 2020